AR100625A1 - Formulación de ceritinib - Google Patents
Formulación de ceritinibInfo
- Publication number
- AR100625A1 AR100625A1 ARP150101661A ARP150101661A AR100625A1 AR 100625 A1 AR100625 A1 AR 100625A1 AR P150101661 A ARP150101661 A AR P150101661A AR P150101661 A ARP150101661 A AR P150101661A AR 100625 A1 AR100625 A1 AR 100625A1
- Authority
- AR
- Argentina
- Prior art keywords
- ceritinib
- tablet
- pharmaceutical composition
- binder
- dose
- Prior art date
Links
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 title abstract 9
- 229960001602 ceritinib Drugs 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 239000011230 binding agent Substances 0.000 abstract 4
- 239000008187 granular material Substances 0.000 abstract 4
- 238000005550 wet granulation Methods 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
La presente descripción se refiere a una composición farmacéutica que comprende Ceritinib. En particular se dirige a la tableta que se prepara por granulación húmeda, en donde se utiliza povidona como aglutinante. Una característica adicional de la composición es que el fármaco y el aglutinante forman la fase interna, mientras que todos los otros excipientes se añaden en forma de polvo como una fase externa. De esta manera, se evita la adherencia de la composición y se puede lograr una dureza suficiente de la tableta. Reivindicación 1: Una composición farmacéutica que comprende más de 40% y hasta 70% por peso de Ceritinib con base en el peso total de la composición farmacéutica. Reivindicación 3: La composición farmacéutica de acuerdo con la reivindicación 1, que comprende un gránulo que comprende Ceritinib y un aglutinante, en donde el gránulo es obtenible mediante granulación húmeda. Reivindicación 12: Una tableta que comprende Ceritinib obtenible por (i) preparación de gránulos que comprenden Ceritinib y un aglutinante mediante granulación húmeda, (ii) mezclar los gránulos con al menos otro excipiente farmacéutico para obtener una mezcla, y (iii) comprimir la mezcla para obtener la tableta. Reivindicación 14: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 11, o la tableta según la reivindicación 11 ó 12, en donde una dosis de Ceritinib es de al menos 150 y hasta 750 mg, preferiblemente una dosis de Ceritinib es de al menos 150 y hasta 375 mg, más preferiblemente es al menos 300 mg y hasta 375 mg, en particular una dosis de Ceritinib es 300 mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004359P | 2014-05-29 | 2014-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100625A1 true AR100625A1 (es) | 2016-10-19 |
Family
ID=53298568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101661A AR100625A1 (es) | 2014-05-29 | 2015-05-27 | Formulación de ceritinib |
Country Status (27)
Country | Link |
---|---|
US (4) | US20170112834A1 (es) |
EP (1) | EP3148513B1 (es) |
JP (3) | JP6679578B2 (es) |
KR (1) | KR20170008239A (es) |
CN (1) | CN106456640B (es) |
AR (1) | AR100625A1 (es) |
AU (3) | AU2015265470A1 (es) |
BR (1) | BR112016027580A8 (es) |
CA (1) | CA2948291A1 (es) |
CL (1) | CL2016003047A1 (es) |
DK (1) | DK3148513T3 (es) |
EA (1) | EA036922B1 (es) |
EC (1) | ECSP16096826A (es) |
ES (1) | ES2792574T3 (es) |
HU (1) | HUE048950T2 (es) |
IL (1) | IL248835B (es) |
MX (1) | MX2016015736A (es) |
PE (1) | PE20170313A1 (es) |
PH (1) | PH12016502272A1 (es) |
PL (1) | PL3148513T3 (es) |
PT (1) | PT3148513T (es) |
SG (1) | SG11201609208UA (es) |
SI (1) | SI3148513T1 (es) |
TN (1) | TN2016000484A1 (es) |
TW (1) | TWI721946B (es) |
UY (1) | UY36140A (es) |
WO (1) | WO2015181739A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176752B (zh) * | 2015-05-07 | 2020-06-23 | 石药集团中奇制药技术(石家庄)有限公司 | 色瑞替尼药物组合物 |
CN109381440A (zh) * | 2018-11-15 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种艾乐替尼组合物 |
CN113244236B (zh) * | 2021-06-01 | 2023-02-03 | 上海市第一人民医院 | 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632778A (en) * | 1970-06-10 | 1972-01-04 | Hoffmann La Roche | Tablets containing l-dopa |
PL2091918T3 (pl) * | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
BRPI0722383A2 (pt) * | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
EP2090297A1 (en) | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
CN105769792A (zh) | 2010-05-11 | 2016-07-20 | 田边三菱制药株式会社 | 含1-(β-D-吡喃葡糖基)-3-(苯基噻吩基甲基)苯化合物的片剂 |
-
2015
- 2015-05-27 UY UY0001036140A patent/UY36140A/es not_active Application Discontinuation
- 2015-05-27 AR ARP150101661A patent/AR100625A1/es unknown
- 2015-05-27 SI SI201531221T patent/SI3148513T1/sl unknown
- 2015-05-27 HU HUE15727470A patent/HUE048950T2/hu unknown
- 2015-05-27 AU AU2015265470A patent/AU2015265470A1/en not_active Abandoned
- 2015-05-27 EP EP15727470.5A patent/EP3148513B1/en active Active
- 2015-05-27 PL PL15727470T patent/PL3148513T3/pl unknown
- 2015-05-27 EA EA201692310A patent/EA036922B1/ru not_active IP Right Cessation
- 2015-05-27 TW TW104117053A patent/TWI721946B/zh not_active IP Right Cessation
- 2015-05-27 KR KR1020167032886A patent/KR20170008239A/ko not_active Application Discontinuation
- 2015-05-27 JP JP2017514990A patent/JP6679578B2/ja active Active
- 2015-05-27 PE PE2016002399A patent/PE20170313A1/es not_active Application Discontinuation
- 2015-05-27 BR BR112016027580A patent/BR112016027580A8/pt not_active Application Discontinuation
- 2015-05-27 SG SG11201609208UA patent/SG11201609208UA/en unknown
- 2015-05-27 MX MX2016015736A patent/MX2016015736A/es active IP Right Grant
- 2015-05-27 CN CN201580028582.7A patent/CN106456640B/zh active Active
- 2015-05-27 ES ES15727470T patent/ES2792574T3/es active Active
- 2015-05-27 CA CA2948291A patent/CA2948291A1/en not_active Abandoned
- 2015-05-27 PT PT157274705T patent/PT3148513T/pt unknown
- 2015-05-27 DK DK15727470.5T patent/DK3148513T3/da active
- 2015-05-27 TN TN2016000484A patent/TN2016000484A1/en unknown
- 2015-05-27 US US15/313,367 patent/US20170112834A1/en not_active Abandoned
- 2015-05-27 WO PCT/IB2015/053966 patent/WO2015181739A1/en active Application Filing
-
2016
- 2016-11-08 IL IL248835A patent/IL248835B/en active IP Right Grant
- 2016-11-15 PH PH12016502272A patent/PH12016502272A1/en unknown
- 2016-11-28 CL CL2016003047A patent/CL2016003047A1/es unknown
- 2016-12-28 EC ECIEPI201696826A patent/ECSP16096826A/es unknown
-
2018
- 2018-05-01 AU AU2018203007A patent/AU2018203007B2/en not_active Ceased
- 2018-09-26 US US16/142,263 patent/US20190022095A1/en not_active Abandoned
-
2019
- 2019-09-16 US US16/571,229 patent/US11000523B2/en active Active
- 2019-09-20 AU AU2019232937A patent/AU2019232937B2/en not_active Ceased
-
2020
- 2020-03-17 JP JP2020046475A patent/JP7084955B2/ja active Active
-
2021
- 2021-02-05 US US17/168,265 patent/US20210154194A1/en active Pending
-
2022
- 2022-03-08 JP JP2022034913A patent/JP2022078236A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201700169A (es) | Derivados de sulfamoilarilamida ciclados y uso de los mismos como medicamentos para el tratamiento de la hepatitis b | |
NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
CR20160006A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
AR100625A1 (es) | Formulación de ceritinib | |
AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
ECSP19024033A (es) | Composiciones de tesofensina | |
ECSP17008187A (es) | Formas de dosificación farmacéutica | |
PH12015501313B1 (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
UY35526A (es) | Derivados de espiroindolina y composiciones farma céuticas de los mismos | |
BR112015022925A2 (pt) | partículas de resina de fenilefrina e seu uso em formulações farmacêuticas | |
CO2018005367A2 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |